Pasithea Financial Statements From 2010 to 2026

KTTA Stock

USD 0.91 0.02 2.15%

Pasithea Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Pasithea Therapeutics' valuation are provided below:

Gross Profit

-2.2 K

Market Capitalization

25.1 M

Enterprise Value Revenue

277.4414

Revenue

486.6 K

Earnings Share

(4.43)

We have found one hundred eight available trending fundamental ratios for Pasithea Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Pasithea Therapeutics recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of January 22, 2026, Market Cap is expected to decline to about 3.8 M. The current year's Enterprise Value is expected to grow to about (3.8 M)

Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 783.7 K, Interest Expense of 224 or Other Operating Expenses of 10.4 M, as well as many indicators such as Price To Sales Ratio of 2.2 K, Dividend Yield of 0.0 or PTB Ratio of 0.26. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.

Build AI portfolio with Pasithea Stock

Check out the analysis of Pasithea Therapeutics Correlation against competitors.

Pasithea Therapeutics Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

31 M

18.5 M

11.3 M

Slightly volatile

Other Current Liabilities

959.6 K

1.3 M

392.7 K

Slightly volatile

Total Current Liabilities

1.3 M

516.4 K

Slightly volatile

Total Stockholder Equity

29.1 M

17 M

10.6 M

Slightly volatile

Net Tangible Assets

62.1 M

59.1 M

19.4 M

Slightly volatile

Accounts Payable

1.2 M

1.3 M

482.1 K

Slightly volatile

Cash

5.9 M

6.2 M

7.3 M

Slightly volatile

Cash And Short Term Investments

5.9 M

6.2 M

7.3 M

Slightly volatile

Common Stock Shares Outstanding

1.2 M

1.3 M

868.7 K

Slightly volatile

Liabilities And Stockholders Equity

31 M

18.5 M

11.3 M

Slightly volatile

Other Current Assets

460.5 K

512.4 K

182.9 K

Slightly volatile

Other Stockholder Equity

52.5 M

74 M

21.7 M

Slightly volatile

Total Liabilities

1.9 M

1.5 M

707 K

Slightly volatile

Net Invested Capital

29.1 M

17 M

10.6 M

Slightly volatile

Total Current Assets

6.3 M

6.6 M

7.5 M

Slightly volatile

Capital Stock

119

125

11.8 K

Slightly volatile

Net Working Capital

5.3 M

5.6 M

7 M

Slightly volatile

Common Stock

119

125

10.7 K

Slightly volatile

Other Liabilities

1.2 M

1.3 M

1.4 M

Slightly volatile

Property Plant And Equipment Gross

140.8 K

148.2 K

131.8 K

Slightly volatile

Property Plant Equipment

16.1 K

18.1 K

19.8 K

Slightly volatile

Short and Long Term Debt Total

69.8 K

73.5 K

403.7 K

Slightly volatile

Net Receivables

34.6 K

36.5 K

240 K

Slightly volatile

Short Term Debt

96.8 K

73.5 K

142.3 K

Slightly volatile

Intangible Assets

6.4 M

6.6 M

8.2 M

Slightly volatile

Other Assets

0.8

0.9

0.9824

Slightly volatile

Short Term Investments

5.5 B

6.2 B

6.8 B

Slightly volatile

Pasithea Therapeutics Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

783.7 K

746.4 K

206.5 K

Slightly volatile

Other Operating Expenses

10.4 M

16.4 M

4.4 M

Slightly volatile

Total Operating Expenses

10.4 M

16.4 M

4.4 M

Slightly volatile

Selling General Administrative

7.7 M

8.1 M

468.6 M

Pretty Stable

Cost Of Revenue

783.7 K

746.4 K

178.8 K

Slightly volatile

Reconciled Depreciation

783.7 K

746.4 K

161.5 K

Slightly volatile

Selling And Marketing Expenses

9.5 B

9.1 B

2 B

Slightly volatile

Pasithea Therapeutics Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation

783.7 K

746.4 K

167.6 K

Slightly volatile

Capital Expenditures

2.18

2.3

9.6 K

Slightly volatile

End Period Cash Flow

5.9 M

6.2 M

7.3 M

Slightly volatile

Change To Liabilities

532.1 K

506.8 K

171.2 K

Slightly volatile

Stock Based Compensation

734.9 K

889.7 K

557.7 K

Slightly volatile

Begin Period Cash Flow

28.2 M

18.8 M

9 M

Slightly volatile

Issuance Of Capital Stock

31 M

24.4 M

43.5 M

Slightly volatile

Dividends Paid

287.7 M

323.7 M

353.3 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

2.2 K

2.4 K

2.7 K

Slightly volatile

PTB Ratio

0.26

0.27

132

Slightly volatile

Book Value Per Share

17.72

12.14

8.4768

Slightly volatile

Average Payables

408.9 K

503.9 K

176.1 K

Slightly volatile

Stock Based Compensation To Revenue

25.03

28.16

30.7353

Slightly volatile

Capex To Depreciation

0.0

12.2468

Slightly volatile

PB Ratio

0.26

0.27

132

Slightly volatile

Payables Turnover

0.0028

0.0031

0.0034

Slightly volatile

Capex To Revenue

1.14

1.28

1.402

Slightly volatile

Cash Per Share

6.9

7.26

6.4447

Slightly volatile

Days Payables Outstanding

84.9 K

95.5 K

104.3 K

Slightly volatile

Income Quality

1.2

1.15

1.0135

Slightly volatile

Intangibles To Total Assets

0.3

0.48

0.2645

Slightly volatile

Net Debt To EBITDA

0.56

0.59

8.6208

Slightly volatile

Current Ratio

7.19

7.57

34.0039

Slightly volatile

Tangible Book Value Per Share

6.19

6.51

6.1199

Slightly volatile

Shareholders Equity Per Share

17.72

12.14

8.4768

Slightly volatile

Debt To Equity

0.0038

0.004

0.0099

Slightly volatile

Capex Per Share

0.0

0.0077

Slightly volatile

Graham Net Net

5.62

5.92

5.8681

Slightly volatile

Revenue Per Share

0.0105

0.0118

0.0129

Slightly volatile

Interest Debt Per Share

0.0553

0.0583

0.0381

Slightly volatile

Debt To Assets

0.0034

0.0036

0.0093

Slightly volatile

Enterprise Value Over EBITDA

0.28

0.29

2.0749

Slightly volatile

Price Book Value Ratio

0.26

0.27

132

Slightly volatile

Days Of Payables Outstanding

84.9 K

95.5 K

104.3 K

Slightly volatile

Ebt Per Ebit

0.67

0.88

0.6008

Slightly volatile

Company Equity Multiplier

0.86

0.98

1.0261

Pretty Stable

Total Debt To Capitalization

0.0038

0.004

0.0098

Slightly volatile

Debt Equity Ratio

0.0038

0.004

0.0099

Slightly volatile

Quick Ratio

7.19

7.57

34.0039

Slightly volatile

Net Income Per E B T

1.22

1.18

1.171

Slightly volatile

Cash Ratio

6.75

7.11

33.4225

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

1.1

1.15

1.0157

Slightly volatile

Price To Book Ratio

0.26

0.27

132

Slightly volatile

Fixed Asset Turnover

0.6

0.67

0.7351

Slightly volatile

Enterprise Value Multiple

0.28

0.29

2.0749

Slightly volatile

Debt Ratio

0.0034

0.0036

0.0093

Slightly volatile

Price Sales Ratio

2.2 K

2.4 K

2.7 K

Slightly volatile

Asset Turnover

2.0E-4

3.0E-4

Slightly volatile

Price Fair Value

0.26

0.27

132

Slightly volatile

Pasithea Therapeutics Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

3.8 M

4 M

35.9 M

Slightly volatile

Pasithea Fundamental Market Drivers

Pasithea Upcoming Events

	12th of February 2024 Upcoming Quarterly Report	View
	31st of December 2023 Next Fiscal Quarter End	View

About Pasithea Therapeutics Financial Statements

Pasithea Therapeutics stakeholders use historical fundamental indicators, such as Pasithea Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Pasithea Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pasithea Therapeutics' assets and liabilities are reflected in the revenues and expenses on Pasithea Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pasithea Therapeutics Corp. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Current Deferred Revenue	-2.3 M	-2.4 M
Cost Of Revenue	746.4 K	783.7 K
Stock Based Compensation To Revenue	28.16	25.03
Capex To Revenue	1.28	1.14
Revenue Per Share	0.01	0.01
Ebit Per Revenue	(269.33)	(282.80)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

GOOG	Alphabet Inc Class C
V	Visa Class A
MSFT	Microsoft

When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:

How To Invest In Pasithea

Details

Is Pasithea Stock a good investment?

Details

What is Pasithea Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Pasithea Therapeutics Correlation against competitors.

You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.43)

Revenue Per Share

0.37

Quarterly Revenue Growth

14.981

Return On Assets

(0.54)

Return On Equity

(0.90)

The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Pasithea Financial Statements From 2010 to 2026

Pasithea Therapeutics Balance Sheet

Pasithea Therapeutics Income Statement

Pasithea Therapeutics Cash Flow Statement

Financial Ratios

Pasithea Therapeutics Valuation Data

Pasithea Fundamental Market Drivers

Pasithea Upcoming Events

About Pasithea Therapeutics Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY